Sulfate is critical in the biotransformation of multiple compounds via sulfation. These compounds include neurotransmitters, proteoglycans, xenobiotics, and hormones such as dehydroepiandrosterone (DHEA). Sulfation reactions are thought to be rate-limited by endogenous sulfate concentrations. The gene, SLC13A1 , encodes the sodium-sulfate cotransporter NaS1, responsible for sulfate (re)absorption in the intestines and kidneys. We previously reported two rare, non-linked, nonsense variants in SLC13A1 (R12X and W48X) associated with hyposulfatemia ( P = 9 × 10− 20).
To examine the effect of serum sulfate concentration and sulfate-lowering genotype on DHEA homeostasis.
Retrospective cohort study.
Academic research.
Participants of the Amish Pharmacogenomics of Anti-Platelet Intervention (PAPI) Study and the Amish Hereditary and Phenotype Intervention (HAPI) Study.
DHEA, DHEA-S, and DHEA-S/DHEA ratio.
Increased serum sulfate was associated with decreased DHEA-S ( P = 0.03) and DHEA-S/DHEA ratio ( P = 0.06) in males but not females. Female SLC13A1 nonsense variant carriers, who had lower serum sulfate ( P = 9 × 10− 1 3 ), exhibited 14% lower DHEA levels ( P = 0.01) and 7% higher DHEA-S/DHEA ratios compared to female non-carriers ( P = 0.002). Consistent with this finding, female SLC13A1 nonsense variant carriers also had lower total testosterone levels compared to non-carrier females ( P = 0.03).
Our results demonstrate an inverse relationship between serum sulfate, and DHEA-S and DHEA-S/DHEA ratio in men, while also suggesting that the sulfate-lowering variants, SLC13A1 R12X and W48X, decrease DHEA and testosterone levels, and increase DHEA-S/DHEA ratio in women. While paradoxical, these results illustrate the complexity of the mechanisms involved in DHEA homeostasis and warrant additional studies to better understand sulfate's role in hormone physiology.